Stock data
| Market cap. | US$237.5m |
| Last close | US$4.12 |
| High / Low (52 weeks) | US$6.0 / US$3.1 |
| Stock market listing | NASDAQ |
| Forecast net cash (US$m) | 5.2 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 4.8346 | (25.8993) | (31.9008) |
| Relative * | 8.3774 | (24.04) | (31.6608) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 14.8 | (30.4) | (33.4) | (72.2) | N/A | N/A |
| 2011A | 7.6 | (40.6) | (44.0) | (82.9) | N/A | N/A |
| 2012E | 1.3 | (46.9) | (50.4) | (79.5) | N/A | N/A |
| 2013E | 0.0 | (51.2) | (54.6) | (86.2) | N/A | N/A |
Last updated on 19/04/2012
Latest research
Expansion of studies
Update | Pharmaceutical & Healthcare | 23/03/2012
Funds to expand studies
Update | Pharmaceutical & Healthcare | 23/01/2012
New ganetespib studies
Update | Pharmaceutical & Healthcare | 04/01/2012
Exploring the GALAXY
Review | Pharmaceutical & Healthcare | 18/08/2011
Twin bet on lung cancer
Outlook | Pharmaceutical & Healthcare | 06/06/2011
Partnership plans firm up
QuickView | Pharmaceutical & Healthcare | 18/03/2011
All eyes on g’pib data
QuickView | Pharmaceutical & Healthcare | 02/03/2011
Investment summary
Synta has confirmed plans to initiate a new, potentially pivotal, Phase II study of ganetespib in ALK-positive non-small cell lung cancer (NSCLC), and a smaller study in metastatic breast cancer (mBC), following its recent $33m fundraising. This means Synta will soon have two registration-directed studies underway with its lead product, cementing ganetespib’s position as the class leader in the HSP90 field. The two new company-sponsored Phase II trials will examine ganetespib as monotherapy in crizotinib-naïve, ALK-positive NSCLC and in mBC. Separate investigator sponsored studies (ISTs) will examine ganetespib in combination with standard chemo in the same settings. A trial was recently initiated to assess ganetespib in relapsed multiple myeloma patients.
Last updated on 23/04/2012
Industry outlook
Ganetespib will be one of around 10 new agents in or entering Phase III trials specifically for second-line NSCLC. The most advanced are Pfizer's Dacomitinib and BI's Afatinib, which are both due to render Phase III results in 2012.
Last updated on 23/04/2012
Key management
| Safi Bahcall, CEO |
| Keith Ehrlich, CFO |
Company address
| 45 Hartwell Avenue, Lexington MA 02421 United States View website |
